• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    Tissue Microarray and Imaging Core

    The Tissue Microarray and Imaging Core is dedicated to the construction and evaluation of high quality tissue microarrays for cancer research

    Community Practice Core

    The Community Practice Core (CPC) offers access to a clinical laboratory of over ten million patients within Harvard Vanguard Medical Associates, Harvard Pilgrim Health Care, and the HMO Cancer Research Network

    Twelve new members join DF/HCC

    Twelve individuals have recently joined DF/HCC

    Bortezomib denies leukemia stem cell development

    Acute myelogenous leukemia (AML), a disease for which treatment has remained relatively unchanged for the past 30 years, is the subject of a new clinical trial featuring a drug aimed at boosting the efficacy of standard induction chemotherapy

    Delivering a one-two punch to the PI3K signaling pathway

    Based largely on original research from a team of DF/HCC investigators, a new clinical trial has launched to determine if combination therapy with a tyrosine kinase inhibitor (neratinib) in combination with an mTOR inhibitor (temsirolimus, Torisel®) can more effectively shut down an important signaling pathway involved in solid tumors like lung and breast cancers

    Co-clinical mouse/human trials aim to speed up drug approvals

    The many breakthroughs in understanding the pathways involved in leukemia have delivered a double-edged sword: hundreds of new drugs await testing but an insufficient patient pool exists to conduct clinical testing in a timely way

    Functional genomics yields drivers, mutations, and pathways in leukemia

    The study of genes, mutations, and collective pathways contributing to leukemia is a cornerstone of the DF/HCC Leukemia Program, led by Thomas Look, MD (DFCI) and co-leaders David Scadden, MD (MGH), Pier Paolo Pandolfi, MD, PhD (BIDMC), and Scott Armstrong, MD, PhD (CHB)

Displaying results 85 to 91 out of 207